Skye Bioscience, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Skye Bioscience, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($55.92M) | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | ($26.57M) | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | ($37.64M) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | ($19.48M) | Mar 22, 2024 |
| FY2022 | Dec 31, 2021 | ($8.52M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($6.56M) | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | $1.05M | Mar 2, 2021 |
| FY2019 | Dec 31, 2018 | ($19.19M) | Mar 23, 2020 |
| FY2018 | Dec 31, 2017 | ($3.09M) | Mar 14, 2019 |
| FY2017 | Dec 31, 2016 | ($3.18M) | Mar 19, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($58.16M) | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | ($30.19M) | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | ($34.74M) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | ($18.31M) | Mar 22, 2024 |
| FY2022 | Dec 31, 2021 | ($7.85M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($6.29M) | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | ($6.63M) | Mar 2, 2021 |
| FY2019 | Dec 31, 2018 | ($4.69M) | Mar 23, 2020 |
| FY2018 | Dec 31, 2017 | ($3.86M) | Mar 14, 2019 |
| FY2017 | Dec 31, 2016 | ($4.47M) | Mar 19, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $6.01M | Mar 31, 2023 |
| FY2022 | Dec 31, 2021 | $2.93M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $1.94M | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | $2.24M | Mar 2, 2021 |
| FY2019 | Dec 31, 2018 | $330.0K | Mar 23, 2020 |
| FY2018 | Dec 31, 2017 | $311.3K | Mar 14, 2019 |
| FY2017 | Dec 31, 2016 | $939.0K | Mar 19, 2018 |
| FY2016 | Dec 31, 2015 | $576.1K | Mar 10, 2017 |
| FY2015 | Dec 31, 2014 | $227.5K | Mar 21, 2016 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($43.06M) | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | ($25.24M) | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | ($13.95M) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | ($12.74M) | Mar 22, 2024 |
| FY2022 | Dec 31, 2021 | ($6.47M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($6.05M) | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | ($6.03M) | Mar 2, 2021 |
| FY2019 | Dec 31, 2018 | ($3.94M) | Mar 23, 2020 |
| FY2018 | Dec 31, 2017 | ($3.33M) | Mar 14, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.3K | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | $1.60M | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | $12.6K | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $28.1K | Mar 22, 2024 |
| FY2022 | Dec 31, 2021 | $90.9K | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $7.2K | Mar 28, 2022 |
| FY2019 | Dec 31, 2018 | $4.4K | Mar 23, 2020 |
| FY2018 | Dec 31, 2017 | $19.7K | Mar 14, 2019 |
| FY2017 | Dec 31, 2016 | $11.1K | Mar 19, 2018 |
| FY2016 | Dec 31, 2015 | $2.0K | Mar 10, 2017 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $28.31M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | $72.76M | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | $11.94M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $9.11M | Mar 22, 2024 |
| FY2022 | Dec 31, 2021 | $9.86M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $2.67M | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | $2.00M | Mar 2, 2021 |
| FY2019 | Dec 31, 2018 | $1.96M | Mar 23, 2020 |
| FY2018 | Dec 31, 2017 | $557.2K | Mar 14, 2019 |
| FY2017 | Dec 31, 2016 | $323.4K | Mar 19, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.29M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | $4.61M | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | $14.07M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $12.12M | Mar 22, 2024 |
| FY2022 | Dec 31, 2021 | $3.99M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $2.22M | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | $1.45M | Mar 2, 2021 |
| FY2019 | Dec 31, 2018 | $17.52M | Mar 23, 2020 |
| FY2018 | Dec 31, 2017 | $1.36M | Mar 14, 2019 |
| FY2017 | Dec 31, 2016 | $1.77M | Mar 19, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $20.02M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | $68.15M | Mar 10, 2026 |
| FY2025 | Dec 31, 2023 | ($2.13M) | Mar 10, 2026 |
| FY2024 | Dec 31, 2022 | ($3.01M) | Mar 20, 2025 |
| FY2023 | Dec 31, 2021 | $5.86M | Mar 22, 2024 |
| FY2022 | Dec 31, 2020 | $450.8K | Mar 31, 2023 |
| FY2021 | Dec 31, 2019 | $548.1K | Mar 28, 2022 |
| FY2020 | Dec 31, 2018 | ($15.56M) | Mar 2, 2021 |
| FY2019 | Dec 31, 2017 | ($3.57M) | Mar 23, 2020 |
| FY2018 | Dec 31, 2016 | ($2.91M) | Mar 14, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($186.87M) | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | ($130.95M) | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | ($104.38M) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | ($66.74M) | Mar 22, 2024 |
| FY2022 | Dec 31, 2021 | ($47.26M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($38.73M) | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | ($32.17M) | Mar 2, 2021 |
| FY2019 | Dec 31, 2018 | ($33.23M) | Mar 23, 2020 |
| FY2018 | Dec 31, 2017 | ($14.03M) | Mar 14, 2019 |
| FY2017 | Dec 31, 2016 | ($10.94M) | Mar 19, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.88M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | $68.42M | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | $1.26M | Mar 20, 2025 |
| FY2018 | Dec 31, 2018 | $1.85M | Mar 14, 2019 |
| FY2018 | Dec 31, 2017 | $260.0K | Mar 14, 2019 |
| FY2017 | Dec 31, 2016 | $64.8K | Mar 19, 2018 |
| FY2017 | Dec 31, 2015 | $3.22M | Mar 19, 2018 |
| FY2016 | Dec 31, 2014 | $207.3K | Mar 10, 2017 |
| FY2015 | Sep 30, 2014 | $1.03M | Mar 21, 2016 |
| FY2013 | Oct 31, 2013 | $52.2K | Jan 27, 2014 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | (5) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | (8) | Mar 22, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | 0 | Mar 2, 2021 |
| FY2019 | Dec 31, 2018 | 0 | Mar 23, 2020 |
| FY2017 | Dec 31, 2017 | 0 | Mar 19, 2018 |
| FY2017 | Dec 31, 2016 | 0 | Mar 19, 2018 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | (5) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | (8) | Mar 22, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | 0 | Mar 2, 2021 |
| FY2019 | Dec 31, 2018 | 0 | Mar 23, 2020 |
| FY2017 | Dec 31, 2017 | 0 | Mar 19, 2018 |
| FY2017 | Dec 31, 2016 | 0 | Mar 19, 2018 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 33.38M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | 30.97M | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | 12.35M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | 3.65M | Mar 22, 2024 |
| FY2022 | Dec 31, 2021 | 476.11M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | 288.07M | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | 182.90M | Mar 2, 2021 |
| FY2019 | Dec 31, 2018 | 133.91M | Mar 23, 2020 |
| FY2018 | Dec 31, 2017 | 33.62M | Mar 14, 2019 |
| FY2017 | Dec 31, 2016 | 21.56M | Mar 19, 2018 |